Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant XELOX + serplulimab + bevacizumab for MSS/pMMR locally advanced right-sided colon cancer
ChiCTR2600127720Phase 2Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in colon adenocarcinoma, sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Pathological complete response (pCR). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600127720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127720.